Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 46 clinical trials
Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia

fluid restriction, are of limited efficacy. Sodium-Glucose-Co-Transporter 2 (SGLT2) inhibitors reduce glucose reabsorption in the proximal tubule, resulting in glucosuria and consecutive osmotic

  • 0 views
  • 05 May, 2021
  • 1 location
Sodium-glucose Co Transporter 2 (sGLT2) Inhibitor and Endogenous Ketone Production

Background The drug Jardiance treats diabetes. It lowers blood sugar by increasing glucose the kidneys excrete. This increases levels of ketones formed in the blood. The body makes ketones when it does not have enough glucose for fuel. The brains of many people with age-related diseases like Alzheimer s do …

  • 84 views
  • 26 Jan, 2021
  • 1 location
Understanding the Cardiovascular Benefits of the Anti-Diabetes Medication SGLT2 Inhibitors

To examine the effect of an increase in plasma beta-hydroxy-butyrate (B-OH-B) levels, spanning the physiologic and pharmacologic range (+0.5, +2.0, and +5.0 mmol/L), on: (i) parameters of left ventricular (LV) systolic and diastolic function utilizing cardiac magnetic resonance imaging (MRI) and (ii) myocardial glucose uptake using positron emission tomography (PET) …

nt-probnp
sglt2
ejection fraction
sglt2 inhibitor
diabetes
  • 106 views
  • 24 Jan, 2021
  • 2 locations
SGLT2 Inhibitor Adjunctive Therapy to Closed Loop Control in Type 1 Diabetes Mellitus

The primary purpose of this study is to evaluate the safety and efficacy of combining SGLT2 inhibitors with closed loop control (CLC).

pramlintide
diabetes
insulin
humalog
glp-1
  • 6 views
  • 24 Apr, 2021
  • 1 location
Effects of SGLT2 Inhibitor on Type 2 Diabetic Patients Undergoing Cardiac Surgery

after cardiac surgery. SGLT2 inhibitors including dapagliflozin as a new diabetes drug can reduce heart failure hospitalization rates and overall cardiovascular mortality in patients with

heart transplantation
sglt2
cardiovascular disease
sglt2 inhibitor
diabetes
  • 0 views
  • 24 Jan, 2021
  • 1 location
Effects of SGLT2 Inhibition on the Mechanisms of Cardiac Damage in the Diabetic Patient With HFpEF

The main aim of this study is to identify the underlying mechanisms of Sodium-glucose co-transporter-2 (SGLT2) inhibitors which are associated to better outcomes in patients with Diabetes

  • 0 views
  • 10 Feb, 2021
  • 1 location
Effects of SGLT2 Inhibition Treatment on Different Levels of Albuminuria in Patients With Type 2 Diabetes

Diabetic kidney disease has become the leading cause for ESRD worldwide.Albuminuria is a major risk factor for progression of diabetic nephropathy. SGLT2 inhibitors are the first antiglycaemic

  • 0 views
  • 23 Jan, 2021
  • 1 location
Effects of the SGLT2-inhibitor Empagliflozin on Patients With Chronic SIADH - the SANDx Study

in correction of hyponatremia, making additional therapy necessary. Empagliflozin is a sodium glucose co-transporter 2 (SGLT2)-inhibitor, which is a well-tolerated treatment option for type 2

aquaretic
serum sodium
sglt2
diabetes
antidiuretic
  • 235 views
  • 05 May, 2021
  • 1 location
Ertugliflozin for Functional Mitral Regurgitation

remain high despite standard medical therapy. Randomized trials to explore cardiovascular (CV) benefit of the sodium-glucose co-transporter-2 (SGLT2) inhibitor have been performed and showed a

  • 0 views
  • 26 Jan, 2021
  • 3 locations
Effect of Empagliflozin on Body Composition and Ketones

The purpose of this study is to evaluate changes of body composition induced by Sodium-glucose cotransporter-2 (SGLT2) inhibitor and its metabolic consequence in Korean type 2 diabetes (T2D).

oral hypoglycemic
hypoglycemic agents
type 2 diabetes mellitus
  • 3 views
  • 04 Apr, 2021
  • 1 location